The C-suite shuffle: Oncopeptides, Zymeworks replace execs to start 2023
Two biotechs are shuffling their C-suites as the calendar turns to the new year: Oncopeptides and Zymeworks.
Oncopeptides announced Wednesday that it’s replacing CEO Jakob Lindberg with Monica Shaw as Lindberg returns to the chief science position. Zymeworks, meanwhile, removed chief medical officer Neil Josephson without naming a replacement. The biotech said Jeffrey Smith, the Alder BioPharmaceuticals founder who engineered a $2 billion sale to Lundbeck in 2019, will take over early R&D.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
